CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia - Wikidata - awgldk - TriplyDB

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q35868355

about

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.CCL2 in chronic lymphocytic leukemia: a macro in microenvironment?Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia.Haematological malignancies: at the forefront of immunotherapeutic innovation.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.Cell Trafficking in Chronic Lymphocytic Leukemia CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation.Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.C-C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.B cell receptor signaling in chronic lymphocytic leukemia.Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis.The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia Relevance of CCL3/CCR5 axis in oral carcinogenesis.Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.

P2860

Q26775506-475C34AB-7A5D-4ED1-B53C-7F748BAA10AA Q26782633-70D00AC5-6548-4087-AE4C-5B0B87E179BE Q33634389-EA024A0F-FB8C-412C-B551-040E5024640C Q33774491-2617623B-E623-4342-A996-7F848C9A6719 Q33924158-1B961D1A-9C34-4F2C-9023-3A4E8403B57D Q33934606-51C731CC-0536-4451-93D8-0656B5F281F0 Q34008559-30F0E0BB-63B7-437B-8AAC-1D1F4BABE6F9 Q34009041-6E5CDD6C-80FA-4E74-A774-C4A79C7B29D3 Q34029869-CA7231AE-B68B-44E5-921D-1D6C4D782CA8 Q34056568-7A15B5D1-1972-4539-8DB6-172436C7F779 Q34240404-3F8776E9-191E-4E90-B2A6-8FF428FA75D5 Q34979505-91A571A9-A1D4-4264-8F16-A13C0781EF16 Q35553576-978436A6-BC9A-4ED9-9AC1-E7F49B542BAC Q35685290-36E5152E-0462-491D-9838-D29AC43A9C84 Q35876037-B49927BC-F404-4054-B74E-9B8119C617D8 Q35880618-B35FCA59-D30A-41D4-9BA9-38E4BFFD9770 Q36021849-2C516249-03C8-436B-A391-29ACEB19BC1D Q36097697-8E48920C-B433-4D5F-AC3E-4088717CF0EC Q36115034-03F53EDD-5559-488A-A656-B69947235A76 Q36470314-12914501-828C-45B2-BF10-578D2B845854 Q36471327-C73A3223-374E-4BB8-9141-8C9FE4677CC7 Q36707753-E77BF3F2-2A79-4DCE-A2A4-6D2B9802C0F3 Q36759124-24087FDC-F648-4441-AA74-B7CCE0979E3C Q36862781-60D8B073-1997-4C9B-912C-4C0551AE4536 Q37125164-994F65B8-1EA6-40A5-AC05-D65FCAC158CE Q37694617-744A5E70-D12B-4CAA-8188-10B8BA367486 Q37706355-1B6D84A5-0BC3-4F76-9DD6-D9BCDD9FB17D Q37959298-7D750937-4D36-484B-9897-9EFE863DD5C7 Q37983913-7FC57117-02AA-4AEF-9672-753B14036BDA Q38124119-2A41010C-2B56-4AF0-A4C6-75658754F4A8 Q38127513-C67C1516-B879-4E46-9AEF-AF1B908632B8 Q38381902-D263890A-2550-4D8C-AB62-FDA0C909A6E1 Q38550810-DB86DCD5-4545-46F9-A3BD-84E792EFF772 Q38616463-07C82A8D-4916-4873-B445-15452C53A84F Q38866630-0982EF44-262C-45BC-9191-841E51F5A2EB Q39722770-A1180A41-8D04-4E89-95AF-B5EBC2950982 Q41012392-1F799516-5A79-49C0-BCCF-C451000539F8 Q41612583-ECFB737B-84D8-4D68-8B7D-D1841312ACC1 Q42221150-D8EEA2F2-8A57-403F-A831-1DE39FAA09B6 Q42363684-464567E1-EC1E-406D-AA7B-0AC70A18B649

P2860

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q35868355

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

CCL3 (MIP-1α) plasma levels an ...... n chronic lymphocytic leukemia

@ast

CCL3 (MIP-1α) plasma levels an ...... n chronic lymphocytic leukemia

@en

type

label

CCL3 (MIP-1α) plasma levels an ...... n chronic lymphocytic leukemia

@ast

CCL3 (MIP-1α) plasma levels an ...... n chronic lymphocytic leukemia

@en

prefLabel

CCL3 (MIP-1α) plasma levels an ...... n chronic lymphocytic leukemia

@ast

CCL3 (MIP-1α) plasma levels an ...... n chronic lymphocytic leukemia

@en

P1433

Q35868355-895DADE7-2B9C-4239-BA79-CC97FA278B08

P1476

Q35868355-C422A426-ACBC-472F-9D4F-6707C25C58CB

P2093

Q35868355-13FA8D7D-2564-4529-AFEB-E50349AAD7B7

Q35868355-3939F0DD-F2C3-403A-A1C8-9FD118D81F2F

Q35868355-4245DCCD-A052-4DA6-BEB3-D4098CFEC3C0

Q35868355-4A42D42C-4226-459B-9094-98A6D2D6B6C2

Q35868355-55875D58-317F-4F74-8FFA-809B368354C6

Q35868355-7F57FECD-B556-487F-91D3-A7BE2409B3FC

Q35868355-8B3AF02F-528B-4AE6-A42A-D83A8EFC0492

Q35868355-8C5C2CAF-37D5-415C-962C-112139F9B4E8

Q35868355-970DB099-ED95-47DD-9B35-10864314080D

Q35868355-A759B52D-81EE-4814-BFA1-1A459373C9AB

P2860

Q35868355-08E6083D-D14F-4088-BE31-BB800244AFFB

Q35868355-0FF1D3F0-B084-461C-BF71-A0DD59D37965

Q35868355-1C3413C7-A078-4E19-9DD2-5D8939C4151C

Q35868355-1CF0D261-4417-4266-8E0B-5E943D3ED0AD

Q35868355-1F82B0C1-D67A-46D1-8427-9A5DC3796305

Q35868355-23358F04-D2CF-4020-867A-67DD807E51F5

Q35868355-31C9AF6E-C13D-4289-A502-D14FC51A3C6E

Q35868355-369E3433-1134-4BDD-940F-C57B4CAC38D5

Q35868355-39BB63DF-1C7C-420E-A880-D65FC364C3AF

Q35868355-39BEB435-FB52-409C-BC9D-A7614F0A7B54

P304

Q35868355-B0E070CF-9373-44F3-9BA7-69F8D7F4B9BA

P31

Q35868355-BA79A37D-E2F6-4B23-8703-DB9D9FBC766D

P356

Q35868355-D4915D19-FECA-474D-B090-BB9ED2E0C195

P407

Q35868355-B816EE84-7DA7-4D7C-B351-1CF90CB122A9

P433

Q35868355-35025E05-EFE2-4BBD-A9E8-FA34A6C08D73

P478

Q35868355-F1FFE55A-8F84-4EF7-A5D9-EC3CAE529361

P50

Q35868355-3848F7F4-C4F6-47EF-87C2-A116275589ED

Q35868355-393CA2FE-3FB1-44E1-85CF-D2692D605D42

Q35868355-4369BB3D-7A06-4ED8-9671-9A498D93A56D

Q35868355-548D29D4-DDBB-4A31-89AF-3E632E0772F1

Q35868355-72EB18B8-2CD8-4904-B958-EB7FEFD672E7

P577

Q35868355-CBFBDD81-18E4-4361-B912-92BCF23D6386

P5875

Q35868355-97DF3522-3F79-45AA-A207-D4E177D8BEF0

P698

Q35868355-EDF88F19-2533-4FD4-8AB5-EF3D5D73B2D6

P921

Q35868355-3F74BC3B-42D3-4970-8C09-44EEB6DAAC27

P932

Q35868355-32F09E05-1C65-4DDC-8AFC-00B5EEA08D5D

P356

BLOOD-2010-09-307249

P1433

P1476

CCL3 (MIP-1α) plasma levels an ...... n chronic lymphocytic leukemia

@en

P2093

Andreas Rosenwald

http://www.w3.org/2001/XMLSchema#string

Diana Krupnik

http://www.w3.org/2001/XMLSchema#string

Donna Neuberg

http://www.w3.org/2001/XMLSchema#string

Elena Hartmann

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Laura Rassenti

http://www.w3.org/2001/XMLSchema#string

Lianchun Xiao

http://www.w3.org/2001/XMLSchema#string

Lillian Werner

http://www.w3.org/2001/XMLSchema#string

Mariela Sivina

http://www.w3.org/2001/XMLSchema#string

Ruth LaPushin

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Genomic aberrations and survival in chronic lymphocytic leukemia

B cells and professional APCs recruit regulatory T cells via CCL4

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

Chronic lymphocytic leukemia

Clinical staging of chronic lymphocytic leukemia.

Comprehensive assessment of chemokine expression profiles by flow cytometry

P304

1662-1669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-09-307249

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

William G Wierda

Michael J. Keating

P577

2010-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49643687

http://www.w3.org/2001/XMLSchema#string

P698

21115978

http://www.w3.org/2001/XMLSchema#string

P921

P932

3318778

http://www.w3.org/2001/XMLSchema#string